Publication | Closed Access

VARIAR Study: Assessment of Short-term Efficacy and Safety of Rituximab Compared to an Tumor Necrosis Factor Alpha Antagonists as Second-line Drug Therapy in Patients With Rheumatoid Arthritis Refractory to a First Tumor Necrosis Factor Alpha Antagonist

Rituximab ComparedRheumatologyRheumatoid DisorderAnti-inflammatoryRheumatoid Arthritis RefractoryVariar StudyMedicineRheumatic DiseasesImmunologyPharmacologyTherapeutic EfficacyInflammatory Rheumatic DiseasePharmacotherapyPsoriatic ArthritisRheumatoid Arthritis